{"literatureAnnotation":{"id":827856309,"history":[],"literature":{"id":6639610,"resourceId":"19500084","title":"Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease.","authors":["Smith M A","Marinaki A M","Arenas M","Shobowale-Bakre M","Lewis C M","Ansari A","Duley J","Sanderson J D"],"journal":"Alimentary pharmacology & therapeutics","month":8,"page":"375-84","pubDate":"2009-08-01T00:00:00-07:00","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/19500084","summary":"BACKGROUND: Azathioprine (AZA) pharmacogenetics are complex and much studied. Genetic polymorphism in TPMT is known to influence treatment outcome. Xanthine oxidase/dehydrogenase (XDH) and aldehyde oxidase (AO) compete with TPMT to inactivate AZA.\n\nOBJECTIVE: To assess whether genetic polymorphism in AOX1, XDH and MOCOS (the product of which activates the essential cofactor for AO and XDH) is associated with AZA treatment outcome in IBD.\n\nMETHODS: Real-time PCR was conducted for a panel of single nucleotide polymorphism (SNPs) in AOX1, XDH and MOCOS using TaqMan SNP genotyping assays in a prospective cohort of 192 patients receiving AZA for IBD.\n\nRESULTS: Single nucleotide polymorphism AOX1 c.3404A > G (Asn1135Ser, rs55754655) predicted lack of AZA response (P = 0.035, OR 2.54, 95%CI 1.06-6.13) and when combined with TPMT activity, this information allowed stratification of a patient's chance of AZA response, ranging from 86% in patients where both markers were favourable to 33% where they were unfavourable (P < 0.0001). We also demonstrated a weak protective effect against adverse drug reactions (ADRs) from SNPs XDH c.837C > T (P = 0.048, OR 0.23, 95% CI 0.05-1.05) and MOCOS c.2107A > C, (P = 0.058 in recessive model, OR 0.64, 95%CI 0.36-1.15), which was stronger where they coincided (P = 0.019).\n\nCONCLUSIONS: These findings have important implications for clinical practice and our understanding of AZA metabolism.","type":"article","volume":"30","xrefs":[{"id":565881880,"resource":"PubMed","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/19500084","xrefId":"19500084"},{"id":1449245752,"resource":"Digital Object Identifiers","sameAs":"http://dx.doi.org/10.1111%2Fj.1365-2036.2009.04057.x","xrefId":"10.1111/j.1365-2036.2009.04057.x"}],"year":2009},"relatedObjects":[{"objCls":"Gene","id":"PA24842","symbol":"AOX1","name":"aldehyde oxidase 1"},{"objCls":"Gene","id":"PA134964534","symbol":"MOCOS","name":"molybdenum cofactor sulfurase"},{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"},{"objCls":"Gene","id":"PA37404","symbol":"XDH","name":"xanthine dehydrogenase"},{"objCls":"Chemical","id":"PA448515","name":"azathioprine"}]},"publication":{"id":6639610,"resourceId":"19500084","title":"Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease.","authors":["Smith M A","Marinaki A M","Arenas M","Shobowale-Bakre M","Lewis C M","Ansari A","Duley J","Sanderson J D"],"journal":"Alimentary pharmacology & therapeutics","month":8,"page":"375-84","pubDate":"2009-08-01T00:00:00-07:00","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/19500084","summary":"BACKGROUND: Azathioprine (AZA) pharmacogenetics are complex and much studied. Genetic polymorphism in TPMT is known to influence treatment outcome. Xanthine oxidase/dehydrogenase (XDH) and aldehyde oxidase (AO) compete with TPMT to inactivate AZA.\n\nOBJECTIVE: To assess whether genetic polymorphism in AOX1, XDH and MOCOS (the product of which activates the essential cofactor for AO and XDH) is associated with AZA treatment outcome in IBD.\n\nMETHODS: Real-time PCR was conducted for a panel of single nucleotide polymorphism (SNPs) in AOX1, XDH and MOCOS using TaqMan SNP genotyping assays in a prospective cohort of 192 patients receiving AZA for IBD.\n\nRESULTS: Single nucleotide polymorphism AOX1 c.3404A > G (Asn1135Ser, rs55754655) predicted lack of AZA response (P = 0.035, OR 2.54, 95%CI 1.06-6.13) and when combined with TPMT activity, this information allowed stratification of a patient's chance of AZA response, ranging from 86% in patients where both markers were favourable to 33% where they were unfavourable (P < 0.0001). We also demonstrated a weak protective effect against adverse drug reactions (ADRs) from SNPs XDH c.837C > T (P = 0.048, OR 0.23, 95% CI 0.05-1.05) and MOCOS c.2107A > C, (P = 0.058 in recessive model, OR 0.64, 95%CI 0.36-1.15), which was stronger where they coincided (P = 0.019).\n\nCONCLUSIONS: These findings have important implications for clinical practice and our understanding of AZA metabolism.","type":"article","volume":"30","xrefs":[{"id":565881880,"resource":"PubMed","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/19500084","xrefId":"19500084"},{"id":1449245752,"resource":"Digital Object Identifiers","sameAs":"http://dx.doi.org/10.1111%2Fj.1365-2036.2009.04057.x","xrefId":"10.1111/j.1365-2036.2009.04057.x"}],"year":2009},"related":{"GENE":[{"objCls":"Gene","id":"PA24842","symbol":"AOX1","name":"aldehyde oxidase 1"},{"objCls":"Gene","id":"PA134964534","symbol":"MOCOS","name":"molybdenum cofactor sulfurase"},{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"},{"objCls":"Gene","id":"PA37404","symbol":"XDH","name":"xanthine dehydrogenase"}],"DISEASE":[{"objCls":"Disease","id":"PA446116","name":"Inflammatory Bowel Diseases"}],"CHEMICAL":[{"objCls":"Chemical","id":"PA448515","name":"azathioprine"}]},"variantAnnotations":[{"cases":192,"chemicals":[{"current":true,"resource":"PharmGKB","text":"azathioprine","url":"/chemical/PA448515"}],"genes":[{"current":true,"resource":"PharmGKB","text":"AOX1","url":"/gene/PA24842"}],"id":769170891,"literature":"19500084","literatureUrl":"/pmid/19500084","phenotypeCategories":["efficacy"],"pvalue":"0.035","race":"Mixed Population","significance":"yes","variants":[{"current":true,"resource":"PharmGKB","text":"rs55754655","url":"/variant/PA166155879"}]}]}